Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shanghai Pharmaceutical Accelerates Retail Restructuring

This article was originally published in PharmAsia News

Executive Summary

As part of its restructuring, Shanghai Pharmaceutical (Group) has started consolidating since January its three major pharmaceutical retail companies - Sine Pharmacy, Leiyunshang Pharmacy and Huashi Pharmacy. As the flagship brand, Huashi Pharmacy will serve as the consolidation platform, overseeing Sine and Leiyunshang Pharmacy. Meanwhile, Shanghai Pharma is pumping assets into Huashi to increase the latter's capital. An inside source disclosed that the group's plan for the next three years focuses on accelerating the development of its direct pharmaceutical retail chain business. According to the three-step program, Shanghai Pharma will first complete integration of the group's internal retail business within 2009; it will then adopt a development model of direct selling stores, followed by ways of exploring international collaborations. (Click here for more - Chinese Language)

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts